CCL2 and chronic kidney disease: 2008; Ko et al. 2010; Nishida et al. 2010; Zeng et al. 2014; Cooper et al. 2016; Moriya et al. 2017) or CKD progression (Kamijo et al. 2004; Nishida et al. 2010; Moriya et al. 2017). Similarly, MCP‐1 was also reported as an effective AKI biomarker in basic (Munshi et al. 2011) and clinical researches (Shinke et al. 2015; Moledina et al. 2017).